The thrust of the company's long-term strategy is becoming clearer.By now, pretty much everyone has heard of Novo Nordisk's (NVO -2.09%) widely popular drug for type 2 diabetes, Ozempic. And, as many investors appreciate, when a pharma company mints a winning product, it's only logical for it to leverage the expertise required to develop the product into making new medicines that are even better.On that note, Novo is already moving very aggressively to invent sequels to Ozempic by flexing its financial migh ...